RxDoctor Payments Data

Solomon Paley, MD

Family Medicine · San Antonio, TXNPI 1952409831

Payments from drug & device makers

$136,499in general payments, 2019–2025

Across 1,342 payments — averaging $101.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$119K
  • AstraZeneca$3K
  • AbbVie$3K
  • Novartis$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$1K
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$6881%
  • Speaking & faculty fees$102,10075%
  • Travel & lodging$10,8568%
  • Food & beverage$22,70417%
  • Education$1520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)303$119,149
AstraZeneca98$2,864
AbbVie(2 entities)224$2,709
Novartis46$1,866
Lilly USA, LLC132$1,610
Novo Nordisk96$1,286
Bayer46$913
Johnson & Johnson49$649
GSK37$518
Boehringer Ingelheim29$512
Pfizer32$384
Merck30$347
Amarin Pharma, Inc.28$336
Esperion Therapeutics, Inc.14$279
Nevro Corp.3$262
Astellas Pharma US Inc11$254
Sanofi-aventis U.S. LLC15$236
Antares Pharma, Inc.14$178
Gilead5$164
Abbott9$154
Kowa Pharmaceuticals America, Inc.10$143
Mannkind Corporation10$135
Takeda Pharmaceuticals U.S.A., Inc.9$128
Shionogi Inc1$96
Supernus Pharmaceuticals, Inc.7$88
Axsome Therapeutics, Inc.4$80
Teva Pharmaceuticals USA, Inc.5$75
Upsher-smith Laboratories LLC5$69
Acerus Pharmaceuticals Corporation4$66
Lundbeck LLC4$63
Althera Pharmaceuticals LLC7$61
Currax Pharmaceuticals LLC4$57
Corcept Therapeutics3$57
Idorsia Pharmaceuticals US Inc3$45
Azurity Pharmaceuticals, Inc.3$44
E.r. Squibb & Sons, L.L.C.3$43
Avanir Pharmaceuticals, Inc.2$41
Bausch Health US, LLC3$40
Radius Health, Inc.3$39
Sanofi Pasteur Inc.2$39
Shield Therapeutics Inc2$38
Phathom Pharmaceuticals, Inc.2$37
Exact Sciences2$32
Zyla Life Sciences, Inc.2$26
Jazz Pharmaceuticals Inc.2$23
Biohaven Pharmaceutical Holding Company Ltd.1$21
Nalpropion Pharmaceuticals LLC1$18
Otsuka America Pharmaceutical, Inc.1$18
Biogen1$15
Vanda Pharmaceuticals Inc.1$14
Biohaven Pharmaceuticals, Inc.1$14
Regeneron Healthcare Solutions, Inc.1$14
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$14
Almatica Pharma LLC1$14
Vistapharm, Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
Corium, LLC1$13
IBSA Pharma Inc.1$13
Aytu Biopharma, Inc.1$13
Paratek Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,499 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$300,556
Medicare patients
675
Services billed
3,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide220$286,160
JardianceEmpagliflozin137$151,514
FarxigaDapagliflozin Propanediol124$137,069
MounjaroTirzepatide86$127,076
EliquisApixaban118$91,457
TrulicityDulaglutide36$50,803
Repatha SureclickEvolocumab46$36,475
XareltoRivaroxaban40$32,753
Xigduo XrDapaglifloz Propaned/Metformin26$32,640
InvokanaCanagliflozin19$24,526
RybelsusSemaglutide11$21,809
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$14,450
LinzessLinaclotide21$12,952
EntrestoSacubitril/Valsartan12$11,884
VascepaIcosapent Ethyl23$11,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,286$307,969231 claims
Lilly USA, LLCMounjaro, Trulicity$1,610$177,879122 claims
Boehringer IngelheimJardiance$512$151,514137 claims
AstraZenecaFarxiga$2,864$137,069124 claims
PfizerEliquis$384$91,457118 claims
Johnson & JohnsonXarelto, Invokana$649$57,27859 claims
AbbVieLinzess, Synthroid$2,709$18,075106 claims
NovartisEntresto$1,866$11,88412 claims
GSKBreo Ellipta$518$11,64323 claims
Astellas Pharma US IncMyrbetriq$254$11,17412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →